Cell and gene therapies represent one of the most transformative advances in modern medicine, offering potential cures for cancers, genetic disorders, and other intractable diseases. Yet, their global distribution tells a story of profound disparity. While patients in the United States and Europe increasingly benefit from therapies like CAR-T and tumor-infiltrating lymphocyte (TIL) treatments, access across much of Asia, Latin America, Africa, and Oceania remains negligible. A 2024 study highlighted that few countries outside of the US and Europe even have specific regulations for clinical evaluation and approval of advanced therapy medicinal product (ATMP), creating a growing “therapeutic gap”.

Bridging this gap requires more than shipping drugs; it demands transferring the complex, hands-on expertise and infrastructure needed to manufacture and deliver these living medicines. Enter CTMC, a joint venture between Resilience + MD Anderson Cancer Center. Earlier this year, CTMC announced the launch of its Global Network Alliance, a pioneering cell therapy manufacturing ecosystem to democratize knowledge and capability.

At the helm of this ambitious effort is Amy Hay, CTMC’s Chief Business Officer. In an interview with the Drug and Device World, Hay outlined the alliance’s vision to move beyond a centralized model and instead foster self-sufficient, regional hubs of excellence. She also notes the challenges of replicating a complex biomedical model, the non-negotiables for partnership, and the delicate balance between global scale and unwavering quality.

Democratization Through Knowledge Sharing

From the outset, Hay is clear: CTMC’s goal is not to build satellite facilities worldwide but to enable others. “Our intent is to share our knowledge globally,” she says. “Our intent is not to set up CTMCs all over the world.”

This philosophy forms the bedrock of the Global Network Alliance. The initiative, officially launched with a partnership agreement with Hospital Israelita Albert Einstein in São Paulo, Brazil, aims to create a collaborative ecosystem. The alliance’s stated vision is to “democratize cell therapy on a global scale by sharing knowledge,” focusing on education, process sharing, and providing access to critical proprietary reagents and materials often scarce in emerging markets.

“Our mandate is to continue to develop this ecosystem on a global scale that supports cell therapy,” Hay explains. The ultimate measure of success is clinical: seeing patients in new regions receive these therapies for the first time within standardized, high-quality trials.

The Replicability vs. Localization Challenge

A central tension in any global health initiative is determining what can be standardized and what must be adapted. Hay identifies several “replicable” components that the alliance actively exports:

• Training and Expertise: A cornerstone is hands-on, immersive training. The program brings international researchers and clinicians to CTMC’s Houston center for three to six months, embedding them in the process. This is coupled with virtual training and continuous education to build local expertise.
• Access to Materials: “Getting things like viral vectors is very hard, very complicated, very expensive” in many countries, Hay notes. The alliance provides a channel for partners to obtain these crucial, often proprietary, manufacturing components.
• Process Documentation: CTMC shares its foundational documents, such as Standard Operating Procedures (SOPs) and master batch records, providing a proven blueprint for quality and compliance.

However, certain barriers are immutable and require local solutions. “The local environment and … the approach to construction … and even local regulations are things that have to be adapted,” Hay states. Regulatory frameworks for advanced therapies are immature or non-existent in many regions. While CTMC can guide partners based on its experience with the US FDA and European Medicines Agency, it cannot navigate local bureaucracies for them.

Infrastructure, particularly building and maintaining Good Manufacturing Practice (GMP)-grade clean rooms, is another localized challenge. CTMC’s approach is to support local construction with international engineering oversight, blending global standards with on-the-ground reality.

The Partner Profile: Building on Existing Foundations

CTMC is not starting from scratch with every partner. Strategic selection is key. The alliance seeks institutions with an “academic bend”, that is, a demonstrated commitment to research and clinical trials. Einstein Hospital was an “ideal first partner,” Hay says, because it already had an advanced CAR-T program, providing a foundation of expertise to build upon.

“We look for partners that have that interest and intent to pursue research and to conduct clinical trials with us,” she adds. For regions just beginning their journey, the requirement shifts to a clear need and a commitment to develop foundational elements, like establishing a TIL tumor bank.

Hay also emphasizes a needs-based geographical strategy. She points to Australia and New Zealand, which have the world’s highest rates of melanoma – a cancer where TIL therapy has shown remarkable efficacy – yet have no local TIL therapy programs. “There is a desire and a need… and an obligation, in a way, for us to share our knowledge,” she states, highlighting regions like the Asia-Pacific (outside China and Japan), the Middle East, and Africa as future priorities.

Scaling Without Compromising Quality

A paramount concern when expanding complex therapies is maintaining the gold standard of care. Hay stresses that the model is designed to uphold quality, not dilute it.

The comprehensive support system—immersive training, shared SOPs, a global advisory board of experts, and quality-controlled material transfers—creates a “specific educational and information infrastructure.” The goal is for a patient in São Paulo or, eventually, Sydney to receive therapy manufactured to a standard comparable to that in Houston.

This is critical for the long-term vision of global clinical trials. “Knowing that you could start a trial … all over the globe and know that the expertise is at the same standard has tremendous value,” Hay says. It enables research that can accelerate development while ensuring patient safety and data integrity across borders.

The Cost Conundrum and Technological Levers

Beyond expertise and infrastructure, cost remains a colossal barrier. Cell therapies are famously expensive, with price tags often exceeding $300,000 per treatment in the US. Hay acknowledges that addressing cost is integral to increasing adoption.

The alliance attacks this from several angles. Training local staff reduces dependence on expensive expatriate labor, which is a significant component of GMP production costs. Furthermore, Hay points to broader industry initiatives that CTMC is involved in, which look to technology to drive down costs in the long term.

“We are participating in a kind of a global society … looking at additional opportunities that we feel would drive down cost,” she says. This includes using AI and machine learning to accelerate drug discovery and optimize therapy design. Implementing automated, closed-system manufacturing processes to increase efficiency, reduce human error, and lower labor costs.

These innovations, while still evolving, are seen as essential to making these therapies more sustainable and accessible on a global scale.

Defining Success

For Hay and CTMC, success is tangible and patient centered. It is measured in milestones and timelines established with each partner. Using Brazil as an example, she outlines clear goals: initial training and setup in Year 1, launching a non-engineered TIL clinical trial in Years 2-3, and progressing to an engineered TIL trial by Years 3-4.

“Ultimately, increasing access gets us to where we are opening new centers and getting patients that would benefit from TIL therapy in trials in those countries,” she states. The alliance’s success, therefore, is not merely in signing agreements but in activating new clinical trial sites and treating the first patients in regions where these options were previously unreachable.

The CTMC Global Network Alliance presents a nuanced model for equitable health innovation. It moves beyond charity or simple technology transfer, advocating instead for a durable partnership built on shared knowledge, mutual commitment to science, and respect for local context. The road is undeniably hard, fraught with regulatory, infrastructural, and economic hurdles.

Yet, the imperative is clear. As the global burden of cancer and other diseases grows, concentrating life-saving technology in a few hubs is ethically and practically untenable. By aiming to “democratize cell therapy” through education and collaboration, Amy Hay and CTMC are betting that the most replicable and valuable component of their model is not a piece of equipment or a protocol, but a philosophy: that expertise, when shared freely and supported steadfastly, can take root anywhere and benefit patients everywhere.